eye disease
Two experimental treatments, a retinal prosthesis and fetal tissue transplant, restored some vision to people with blinding eye diseases. The findings, presented at Neuroscience 2009, the annual meeting of the Society for Neuroscience and the world's largest source of emerging news on brain science and health, may lead to new treatments for the blind.
A new review published in the Journal of the American Society of Nephrology (JASN) shows how stem cell based therapies in mice can slow down the progression of kidney disease in Alport Syndrome: “Stem Cell Therapies Benefit Alport Syndrome” LeBleu V et al, 2009.
Several cell-based therapy approaches could provide new treatments for patients with Alport syndrome, reports an upcoming paper in the Journal of the American Society of Nephrology (JASN).
DURHAM, N.C. -- Tell-tale signs of a condition that can blind premature babies are being seen for the first time using a new handheld device in a study at Duke University Medical Center.
NEW YORK, September 8, 2009 -- The latest data from groundbreaking human clinical trials of the effectiveness of continuous glucose monitors (CGM) show that the primary determinant of improvements in achieving better diabetes control is regular use of monitors -- six days per week or more -- rather than the age of patients, and that benefits continue well past the time when people with type
BEDFORD, MA ?August, 24, 2009 -- Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced positive data from a Phase 2 clinical study evaluating RX-10045, a resolvin administered as a topical eye drop for the treatment of patients with chronic dry eye syndrome.
AUGUSTA, Ga. - Elevated levels of the enzyme arginase contribute to vascular eye damage and Medical College of Georgia researchers say therapies to normalize its levels could halt progression of potentially blinding diseases such as diabetic retinopathy.
Queen's University Belfast academics have helped develop an antioxidant supplement which may slow down sight loss in elderly people.
The supplement may help those affected by the leading cause of blindness in the Western World, a five-year research programme has found.
In a world-first breakthrough, University of New South Wales (UNSW) medical researchers have used stem cells cultured on a simple contact lens to restore sight to sufferers of blinding corneal disease.
Sight was significantly improved within weeks of the procedure, which is simple, inexpensive and requires a minimal hospital stay.
SAN FRANCISCO, CA--- Highlights of May's Ophthalmology, the journal of the American Academy of Ophthalmology (Academy), include a new analysis of dietary factors and risks for age-related macular degeneration (AMD), and a landmark study on glaucoma treatment cost-effectiveness as linked to vision improvement and quality of life.
Ann Arbor, MI--Patients with a rare, blinding eye disease saw their vision improve after treatment with drugs to suppress their immune systems, according to researchers at the University of Michigan Kellogg Eye Center. Because autoimmune retinopathy (AIR) is difficult to diagnose, the biggest challenge now is to find biologic markers that identify patients who can benefit from treatment.
Ann Arbor, MI--Patients with a rare, blinding eye disease saw their vision improve after treatment with drugs to suppress their immune systems, according to researchers at the University of Michigan Kellogg Eye Center. Because autoimmune retinopathy (AIR) is difficult to diagnose, the biggest challenge now is to find biologic markers that identify patients who can benefit from treatment.
The prevalence of the eye disease age-related macular degeneration is projected to increase substantially by 2050, but the use of new therapies is expected to help mitigate its effects on vision, according to results of simulation modeling reported in the April issue of Archives of Ophthalmology, one of the JAMA/Archives journals.
PITTSBURGH, April 9 - Stem cells collected from human corneas restore transparency and don't trigger a rejection response when injected into eyes that are scarred and hazy, according to experiments conducted in mice by researchers at the University of Pittsburgh School of Medicine. Their study will be published in the journal Stem Cells and appears online today.
A simple way of establishing which preterm infants are at risk of developing the eye disease ROP is to follow their weight gain. A new study from the Sahlgrenska Academy, University of Gothenburg, Sweden, suggests that following weekly weight development might replace the need for considerably more expensive ophthalmological examinations.
